---
figid: PMC5819301__13395_2018_150_Fig8_HTML
figlink: /pmc/articles/PMC5819301/figure/Fig8/
number: Fig. 8
caption: Model of Nilotinib effects on myoblasts and skeletal myogenesis. Nilotinib
  binds to and inhibits p38 MAPK. Consequently, Nilotinib activates the MEK/ERK proliferation
  signaling inhibiting myoblast differentiation. Simultaneously, Nilotinib stimulates
  the AKT survival pathway. In addition, ERK1/2 and AKT stimulation is required for
  Nilotinib-induced myoblast proliferation. The stimulation of proliferation and the
  anti-myogenic effects of Nilotinib through the perturbation of p38, ERK, and AKT
  signaling pathways are illustrated
pmcid: PMC5819301
papertitle: Nilotinib impairs skeletal myogenesis by increasing myoblast proliferation.
reftext: Osvaldo Contreras, et al. Skelet Muscle. 2018;8:5.
pmc_ranked_result_index: '67401'
pathway_score: 0.534567
filename: 13395_2018_150_Fig8_HTML.jpg
figtitle: Nilotinib effects on myoblasts and skeletal myogenesis
year: '2018'
organisms: Homo sapiens
ndex: 62af5dd6-de93-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5819301__13395_2018_150_Fig8_HTML.html
  '@type': Dataset
  description: Model of Nilotinib effects on myoblasts and skeletal myogenesis. Nilotinib
    binds to and inhibits p38 MAPK. Consequently, Nilotinib activates the MEK/ERK
    proliferation signaling inhibiting myoblast differentiation. Simultaneously, Nilotinib
    stimulates the AKT survival pathway. In addition, ERK1/2 and AKT stimulation is
    required for Nilotinib-induced myoblast proliferation. The stimulation of proliferation
    and the anti-myogenic effects of Nilotinib through the perturbation of p38, ERK,
    and AKT signaling pathways are illustrated
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MAP2K1
  - AKT2
  - PIK3CA
  - PIK3CB
  - AKT3
  - AKT1
  - PIK3R5
  - PIK3R4
  - PIK3CD
  - MAPK11
  - PIK3R6
  - MAP2K2
  - MAPK14
  - MAPK12
  - MAPK13
  - PIK3R3
  - PIK3CG
  - Nilotinib
genes:
- word: MEK1/2
  symbol: MEK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: p38
  symbol: p38
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: MEK1/2
  symbol: MEK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: p38
  symbol: p38
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: p38
  symbol: p38
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: p38
  symbol: p38
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
chemicals:
- word: Nilotinib
  source: MESH
  identifier: C498826
diseases: []
---
